Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody Shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice

Journal of Virology

Volumn 88, Issue 18, 2014, Pages 10569-10583

  Boyoglu Barnum, Seyhan ^a   Chirkova, Tatiana ^a   Todd, Sean O ^a   Barnum, Thomas R ^b   Gaston, Kelsey A ^a   Jorquera, Patricia ^b   Haynes, Lia M ^c   Tripp, Ralph A ^b   Moore, Martin L ^a   Anderson, Larry J ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 131 2G; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SPLEEN CELL; TH1 CELL; TH2 CELL; VIRUS LOAD; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; FEMALE; GENETICS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; TH1 CELLS; TH2 CELLS; VIRAL ENVELOPE PROTEINS;

EID: 84906329950     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01503-14     Document Type: Article

References (99)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095-2128. http://dx.doi.org/10.1016/S0140-6736(12)61728-0.
3. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
4. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405-421.
5. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449- 463.
6. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. 1969. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89:435-448.
7. Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J, Osterhaus AD, de Groot R, Corvaia N, Beck A, Bouveret-Le-Cam N, Bonnefoy JY. 2001. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184:1456-1460. http://dx.doi.org/10.1086/324426.
8. Piedra PA, Cron SG, Jewell A, Hamblett N, McBride R, Palacio MA, Ginsberg R, Oermann CM, Hiatt PW. 2003. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multicenter trial in children with cystic fibrosis. Vaccine 21:2448-2460. http: //dx.doi.org/10.1016/S0264-410X(03)00098-7.
9. Munoz FM, Piedra PA, Glezen WP. 2003. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21:3465-3467. http://dx.doi.org/10.1016/S0264 -410X(03)00352-9.
10. Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, Neuzil KM, Nichol KL, Simoes EA, Wright PF, Sales VM. 2008. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines- nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J. Infect. Dis. 198:1317-1326. http://dx.doi.org/10.1086/592168.
11. Boyoglu S, Vig K, Pillai S, Rangari V, Dennis VA, Khazi F, Singh SR. 2009. Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus. Nanomedicine 5:463-472. http: //dx.doi.org/10.1016/j.nano.2009.02.004.
12. Barnum SB, Subbarayan P, Vig K, Pillai S, Dennis VA. 2012. Nanoencapsulated DNA and/or protein boost immunizations increase efficiency of DNA vaccine protection against RSV. J. Nanomed. Nanotechnol. 3:132. http://dx.doi.org/10.4172/2157-7439.1000132.
13. Graham BS. 2011. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol. Rev. 239: 149-166. http://dx.doi.org/10.1111/j.1600-065X.2010.00972.x.
14. Karron RA, Thumar B, Schappell E, Buchholz UJ, Collins PL. 2013. Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines. J. Infect. Dis. 207:1773-1779. http: //dx.doi.org/10.1093/infdis/jit089.
15. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. 2013. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 31(Suppl 2):B209-B215. http://dx.doi.org/10.1016 /j.vaccine.2012.11.106.
16. Falsey AR. 2005. Respiratory syncytial virus infection in elderly and highrisk adults. N. Engl. J. Med. 352:1749-1759. http://dx.doi.org/10.1056 /NEJMoa043951.
17. Henderson FW, Collier AM, Clyde WA, Denny FW. 1979. Respiratorysyncytial- virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N. Engl. J. Med. 300:530-534. http://dx .doi.org/10.1056/NEJM197903083001004.
18. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. 1981. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 98:708-715. http://dx.doi.org/10.1016/S0022-3476(81)80829-3.
19. Hall CB, Walsh EE, Long CE, Schnabel KC. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163:693-698. http://dx.doi.org/10.1093/infdis/163.4.693.
20. Lamprecht CL, Krause HE, Mufson MA. 1976. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J. Infect. Dis. 134:211-217. http://dx.doi.org/10.1093/infdis/134.3.211.
21. Luchsinger V, Piedra PA, Ruiz M, Zunino E, Martinez MA, Machado C, Fasce R, Ulloa MT, Fink MC, Lara P, Avendano LF. 2012. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin. Infect. Dis. 54:905-912. http://dx.doi .org/10.1093/cid/cir955.
22. Stensballe LG, Ravn H, Kristensen K, Agerskov K, Meakins T, Aaby P, Simoes EA. 2009. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J. Allergy Clin. Immunol. 123:398-403. http://dx.doi.org/10 .1016/j.jaci.2008.10.043.
23. Walsh EE, Falsey AR. 2004. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J. Med. Virol. 73:295-299. http://dx.doi.org/10.1002/jmv.20090.
24. Renaud C, Xie H, Seo S, Kuypers J, Cent A, Corey L, Leisenring W, Boeckh M, Englund JA. 2013. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol. Blood Marrow Transplant. 19:1220-1226. http://dx.doi.org/10.1016/j.bbmt.2013.05.005.
25. Swedan S, Andrews J, Majumdar T, Musiyenko A, Barik S. 2011. Multiple functional domains and complexes of the two nonstructural proteins of human respiratory syncytial virus contribute to interferon suppression and cellular location. J. Virol. 85:10090-10100. http://dx.doi.org /10.1128/JVI.00413-11.
26. Schlender J, Walliser G, Fricke J, Conzelmann KK. 2002. Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced Tcell proliferation by contact. J. Virol. 76:1163-1170. http://dx.doi.org/10 .1128/JVI.76.3.1163-1170.2002.
27. Tripp RA. 2004. Pathogenesis of respiratory syncytial virus infection. Viral Immunol. 17:165-181. http://dx.doi.org/10.1089/0882824041310513.
28. Kauvar LM, Harcourt JL, Haynes LM, Tripp RA. 2010. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2:655-661. http://dx.doi.org/10.2217/imt.10.53.
29. Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson LJ. 1999. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 73:7099-7107.
30. Tripp RA, Jones L, Anderson LJ. 2000. Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J. Virol. 74:6227-6229. http://dx.doi.org/10 .1128/JVI.74.13.6227-6229.2000.
31. Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. 2003. Enhanced disease and pulmonary eosinophilia associated with formalininactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J. Virol. 77:9831-9844. http://dx.doi.org/10.1128/JVI.77.18.9831-9844.2003.
32. Tripp RA, Moore D, Winter J, Anderson LJ. 2000. Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J. Virol. 74:1614-1622. http://dx.doi.org/10.1128/JVI.74 .4.1614-1622.2000.
33. Boyoglu-Barnum S, Gaston KA, Todd SO, Boyoglu C, Chirkova T, Barnum TR, Jorquera P, Haynes LM, Tripp RA, Moore ML, Anderson LJ. 2013. A respiratory syncytial virus (RSV) anti-G protein F(ab=)2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J. Virol. 87:10955-10967. http: //dx.doi.org/10.1128/JVI.01164-13.
34. Tripp RA, Dakhama A, Jones LP, Barskey A, Gelfand EW, Anderson LJ. 2003. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J. Virol. 77:6580-6584. http://dx.doi.org/10.1128/JVI.77.11.6580-6584.2003.
35. Anderson LJ, Bingham P, Hierholzer JC. 1988. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J. Virol. 62:4232-4238.
36. Anderson LJ, Hierholzer JC, Stone YO, Tsou C, Fernie BF. 1986. Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. J. Clin. Microbiol. 23:475-480.
37. Radu GU, Caidi H, Miao C, Tripp RA, Anderson LJ, Haynes LM. 2010. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)- challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J. Virol. 84:9632-9636. http://dx.doi.org/10.1128/JVI.00451-10.
38. Miao C, Radu GU, Caidi H, Tripp RA, Anderson LJ, Haynes LM. 2009. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab=)2 components mediates reduced pulmonary inflammation in mice. J. Gen. Virol. 90:1119-1123. http://dx.doi.org/10.1099/vir.0 .009308-0.
39. Haynes LM, Caidi H, Radu GU, Miao C, Harcourt JL, Tripp RA, Anderson LJ. 2009. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J. Infect. Dis. 200:439-447. http://dx.doi.org/10.1086/600108.
40. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE, Jr, Goleniewska K, Williams JV, Collins PL, Peebles RS, Jr. 2009. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J. Virol. 83:4185-4194. http://dx.doi.org/10.1128/JVI.01853-08.
41. Anderson LJ, Hierholzer JC, Bingham PG, Stone YO. 1985. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J. Clin. Microbiol. 22:1050-1052.
42. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
43. Lindell J, Girard P, Muller N, Jordan M, Wurm F. 2004. Calfection: a novel gene transfer method for suspension cells. Biochim. Biophys. Acta 1676:155-161. http://dx.doi.org/10.1016/j.bbaexp.2003.11.016.
44. Varga SM, Wissinger EL, Braciale TJ. 2000. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+T cell responses. J. Immunol. 165:6487-6495. http://dx.doi.org/10.4049/jimmunol.165.11.6487.
45. Kulkarni AB, Morse HC III, Bennink JR, Yewdell JW, Murphy BR. 1993. Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells. J. Virol. 67:4086-4092.
46. Liu J, Ruckwardt TJ, Chen M, Johnson TR, Graham BS. 2009. Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model. J. Virol. 83:4934-4941. http://dx.doi.org/10.1128/JVI .02140-08.
47. Crotty S. 2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29:621-663. http://dx.doi.org/10.1146/annurev-immunol-031210-101400.
48. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. 2000. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192:1553-1562. http://dx.doi.org /10.1084/jem.192.11.1553.
49. Moser B, Schaerli P, Loetscher P. 2002. CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses. Trends Immunol. 23:250-254. http://dx.doi.org/10.1016/S1471-4906(02)02218-4.
50. Jorquera PA, Choi Y, Oakley KE, Powell TJ, Boyd JG, Palath N, Haynes LM, Anderson LJ, Tripp RA. 2013. Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS One 8:e74905. http://dx.doi.org/10.1371/journal.pone.0074905.
51. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655-669. http://dx.doi.org/10.1016/S0092-8674(00)80702-3.
52. Yan L, Xiao-Ling S, Zheng-Yan C, Guo-Ping L, Sen Z, Zhuang C. 2013.HSP70/CD80DNAvaccine inhibits airway remodeling by regulating the transcription factors T-bet and GATA-3 in a murine model of chronic asthma. Arch. Med. Sci. 9:906-915. http://dx.doi.org/10.5114/aoms.2013 .33180.
53. Cook KD, Miller J. 2010. TCR-dependent translational control of GATA-3 enhances Th2 differentiation. J. Immunol. 185:3209-3216. http: //dx.doi.org/10.4049/jimmunol.0902544.
54. Kemp KL, Levin SD, Bryce PJ, Stein PL. 2010. Lck mediates Th2 differentiation through effects on T-bet and GATA-3. J. Immunol. 184:4178-4184. http://dx.doi.org/10.4049/jimmunol.0901282.
55. Rouse BT, Sarangi PP, Suvas S. 2006. Regulatory T cells in virus infections. Immunol. Rev. 212:272-286. http://dx.doi.org/10.1111/j .0105-2896.2006.00412.x.
56. Suvas S, Rouse BT. 2006. Treg control of antimicrobial T cell responses. Curr. Opin. Immunol. 18:344-348. http://dx.doi.org/10.1016/j.coi.2006 .03.005.
57. Ruckwardt TJ, Bonaparte KL, Nason MC, Graham BS. 2009. Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J. Virol. 83:3019-3028. http://dx.doi.org/10.1128/JVI.00036-09.
58. Fulton RB, Meyerholz DK, Varga SM. 2010. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J. Immunol. 185: 2382-2392. http://dx.doi.org/10.4049/jimmunol.1000423.
59. Lee DC, Harker JA, Tregoning JS, Atabani SF, Johansson C, Schwarze J, Openshaw PJM. 2010. CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J. Virol. 84:8790-8798. http://dx.doi .org/10.1128/JVI.00796-10.
60. Durant LR, Makris S, Voorburg CM, Loebbermann J, Johansson C, Openshaw PJM. 2013. Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J. Virol. 87:10946-10954. http://dx.doi.org/10.1128/JVI.01295-13.
61. Tarlinton D, Good-Jacobson K. 2013. Diversity among memory B cells: origin, consequences, and utility. Science 341:1205-1211. http://dx.doi .org/10.1126/science.1241146.
62. McHeyzer-Williams LJ, Pelletier N, Mark L, Fazilleau N, McHeyzer- Williams MG. 2009. Follicular helper T cells as cognate regulators of B cell immunity. Curr. Opin. Immunol. 21:266-273. http://dx.doi.org/10.1016 /j.coi.2009.05.010.
63. Kerfoot SM, Yaari G, Patel JR, Johnson KL, Gonzalez DG, Kleinstein SH, Haberman AM. 2011. Germinal center B cell and T follicular helper cell development initiates in the interfollicular zone. Immunity 34:947-960. http://dx.doi.org/10.1016/j.immuni.2011.03.024.
64. Su C, Duan X, Zheng J, Liang L, Wang F, Guo L. 2013. IFN-α as an adjuvant for adenovirus-vectored FMDV subunit vaccine through improving the generation of T follicular helper cells. PLoS One 8:e66134. http://dx.doi.org/10.1371/journal.pone.0066134.
65. King C, Tangye SG, Mackay CR.2008. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu. Rev. Immunol. 26:741-766. http://dx.doi.org/10.1146/annurev.immunol.26.021607.090344.
66. Dent AL, Shaffer AL Yu X, Allman D, Staudt LM. 1997. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276:589-592. http://dx.doi.org/10.1126/science.276.5312.589.
67. Ye BH, Cattoretti G, Shen Q, Zhang J, Hawe N, de Waard R, Leung C, Nouri-Shirazi M, Orazi A, Chaganti RS, Rothman P, Stall AM, Pandolfi PP, Dalla-Favera R. 1997. The BCL-6 proto-oncogene controls germinalcentre formation and Th2-type inflammation. Nat. Genet. 16:161-170.
68. Kusam S, Toney LM, Sato H, Dent AL. 2003. Inhibition of Th2 differentiation and GATA-3 expression by BCL-6. J. Immunol. 170:2435-2441. http://dx.doi.org/10.4049/jimmunol.170.5.2435.
69. Preston FM, Beier PL, Pope JH. 1992. Infectious respiratory syncytial virus (RSV) effectively inhibits the proliferative T cell response to inactivated RSV in vitro. J. Infect. Dis. 165:819-825.
70. Heidema J, de Bree GJ, De Graaff PM, van Maren WW, Hoogerhout P, Out TA, Kimpen JL, van Bleek GM. 2004. Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J. Gen. Virol. 85:2365-2374. http://dx.doi.org/10.1099/vir.0 .80131-0.
71. Roe MF, Bloxham DM, White DK, Ross-Russell RI, Tasker RT, O'Donnell DR. 2004. Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis. Clin. Exp. Immunol. 137:139-145. http://dx.doi.org /10.1111/j.1365-2249.2004.02512.x.
72. Loebbermann J, Schnoeller C, Thornton H, Durant L, Sweeney NP, Schuijs M, O'Garra A, Johansson C, Openshaw PJ. 2012. IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice. PLoS One 7:e32371. http://dx.doi.org/10.1371/journal .pone.0032371.
73. Weiss KA, Christiaansen AF, Fulton RB, Meyerholz DK, Varga SM. 2011. Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. J. Immunol. 187:3145-3154. http://dx.doi.org/10.4049/jimmunol.1100764.
74. Fulton RB, Meyerholz DK, Varga SM. 2010. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J. Immunol. 185: 2382-2392. http://dx.doi.org/10.4049/jimmunol.1000423.
75. Sun J, Cardani A, Sharma AK, Laubach VE, Jack RS, Muller W, Braciale TJ. 2011. Autocrine regulation of pulmonary inflammation by effector T-cell derived IL-10 during infection with respiratory syncytial virus. PLoS Pathog. 7:e1002173. http://dx.doi.org/10.1371/journal.ppat.1002173.
76. Gonzalez PA, Prado CE, Leiva ED, Carreno LJ, Bueno SM, Riedel CA, Kalergis AM. 2008. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 105:14999-15004. http://dx.doi.org/10.1073/pnas.0802555105.
77. Tsuchida T, Matsuse H, Fukahori S, Kawano T, Tomari S, Fukushima C, Kohno S. 2012. Effect of respiratory syncytial virus infection on plasmacytoid dendritic cell regulation of allergic airway inflammation. Int. Arch. Allergy Immunol. 157:21-30. http://dx.doi.org/10.1159/000324676.
78. Le Nouen C, Hillyer P, Munir S, Winter CC, McCarty T, Bukreyev A, Collins PL, Rabin RL, Buchholz UJ. 2010. Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells. PLoS One 5:e15017. http://dx.doi.org/10.1371/journal.pone.0015017.
79. Bartz H, Turkel O, Hoffjan S, Rothoeft T, Gonschorek A, Schauer U. 2003. Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naive T cells. Immunology 109: 49-57. http://dx.doi.org/10.1046/j.1365-2567.2003.01629.x.
80. Chi B, Dickensheets HL, Spann KM, Alston MA, Luongo C, Dumoutier L, Huang J, Renauld JC, Kotenko SV, Roederer M, Beeler JA, Donnelly RP, Collins PL, Rabin RL. 2006. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J. Virol. 80:5032-5040. http://dx.doi.org/10.1128/JVI.80.10.5032-5040 .2006.
81. Shingai M, Azuma M, Ebihara T, Sasai M, Funami K, Ayata M, Ogura H, Tsutsumi H, Matsumoto M, Seya T. 2008. Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFNbeta induction. Int. Immunol. 20:1169-1180. http://dx.doi.org/10.1093 /intimm/dxn074.
82. Arnold R, Konig B, Werchau H, Konig W. 2004. Respiratory syncytial virus deficient in solubleGprotein induced an increased proinflammatory response in human lung epithelial cells. Virology 330:384-397. http://dx .doi.org/10.1016/j.virol.2004.10.004.
83. Ray R, Hoft DF, Meyer K, Brown R, Lagging LM, Belshe RB. 2001. Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus. Virus Res. 75:147-154. http://dx.doi.org/10.1016/S0168 -1702(01)00237-4.
84. Johnson TR, McLellan JS, Graham BS. 2012. Respiratory syncytial virus glycoproteinGinteracts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. J. Virol. 86:1339-1347. http://dx.doi.org/10.1128/JVI.06096-11.
85. Polack FP, Irusta PM, Hoffman SJ, Schiatti MP, Melendi GA, Delgado MF, Laham FR, Thumar B, Hendry RM, Melero JA, Karron RA, Collins PL, Kleeberger SR. 2005. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc. Natl. Acad. Sci. U. S. A. 102:8996-9001. http://dx .doi.org/10.1073/pnas.0409478102.
86. Oshansky CM, Zhang W, Moore E, Tripp RA. 2009. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 4:279-297. http://dx.doi.org/10.2217/fmb .09.1.
87. Bukreyev A, Serra ME, Laham FR, Melendi GA, Kleeberger SR, Collins PL, Polack FP. 2006. The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes. J. Virol. 80:5854-5861. http://dx.doi .org/10.1128/JVI.02671-05.
88. Melendi GA, Bridget D, Monsalvo AC, Laham FF, Acosta P, Delgado MF, Polack FP, Irusta PM. 2011. Conserved cysteine residues within the attachmentGglycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses. Virus Genes 42:46-54. http://dx.doi.org/10.1007/s11262-010-0545-9.
89. Johnson PR, Olmsted RA, Prince GA, Murphy BR, Alling DW, Walsh EE, Collins PL. 1987. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J. Virol. 61:3163- 3166.
90. Sullender W. 1995. Antigenic analysis of chimeric and truncated G proteins of respiratory syncytial virus. Virology 209:70-79.
91. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2:732-738. http://dx.doi.org/10.1038/90675.
92. D'Haese JG, Demir IE, Friess H, Ceyhan GO. 2010. Fractalkine/ CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin. Ther. Targets 14:207-219. http://dx .doi.org/10.1517/14728220903540265.
93. Mionnet C, Buatois V, Kanda A, Milcent V, Fleury S, Lair D, Langelot M, Lacoeuille Y, Hessel E, Coffman R, Magnan A, Dombrowicz D, Glaichenhaus N, Julia V. 2010. CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat. Med. 16:1305-1312. http://dx.doi.org/10.1038/nm.2253.
94. Garcia J, Pino PA, Mizutani M, Cardona SM, Charo IF, Ransohoff RM, Forsthuber TG, Cardona AE. 2013. Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation. J. Immunol. 191:1063-1072. http://dx.doi.org/10.4049/jimmunol.1300040.
95. Becker Y. 2006. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy-a review. Virus Genes 33:235-252. http://dx.doi.org/10.1007/s11262-006-0064-x.
96. Sparer TE, Matthews S, Hussell T, Rae AJ, Garcia-Barreno B, Melero JA, Openshaw PJM. 1998. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187:1921-1926.
97. Tebbey P, Hagen M, Hancock G. 1998. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188:1967-1972.
98. Elliott MB, Pryharski KS, Yu Q, Boutilier LA, Campeol N, Melville K, Laughlin TS, Gupta CK, Lerch RA, Randolph VB, LaPierre NA, Dack KM, Hancock GE. 2004. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. J. Virol. 78:8446-8454. http://dx.doi.org/10.1128/JVI.78.16.8446-8454.2004.
99. Melendi GA, Bridget D, Monsalvo AC, Laham FF, Acosta P, Delgado MF, Polack FP, Irusta PM. 2011. Conserved cysteine residues within the attachmentGglycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses. Virus Genes 42:46-54. http://dx.doi.org/10.1007/s11262-010-0545-9.